(MENAFN- News Direct) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022.
Saviuk tells Proactive this marks the 5th consecutive quarter of growth for the company, with adjusted gross profit increasing by 178% to $4.2 million from a year earlier.
Physicians prescribing Enerzair and Atectura reached 1,583 at the end of the first quarter, 39% growth for the quarter and a 799% increase year-over-year. Total annual Enerzair and Atectura prescriptions surpassed 34,000 at the end of 1Q 2023, up 1,917% year-over-year. --p
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.